Category: chronic migraine
AbbVie’s Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category currently dominated by injectable therapies. The phase 3 PROGRESS trial showed that taking Qulipta (atogepant) every day – ether in a once-daily […]
Shots: The P-IV HER-MES study evaluates the tolerability & efficacy of Aimovig (70/140mg) vs topiramate in 777 patients with episodic or chronic migraine (≥4 migraine days/month) prior to not being treated with migraine prevention treatment or previously failed up to 3 previous therapies. The study was conducted in collaboration with Novartis at 82 study sites […]
UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in […]